JN Medsys
JN Medsys is a Singapore-headquartered life science tools company that develops chip-based digital PCR instruments, consumables, assay kits, and laboratory services for absolute nucleic acid quantification, serving academic, clinical diagnostics, and industrial customers across Asia-Pacific via direct sales and eight regional distributors.
- Company typePrivate
- Founded2016
- HeadquartersBeijing, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What JN Medsys does
JN Medsys is a privately held life science tools company headquartered in Singapore (with Beijing also cited as a founding location) that develops and commercializes a chip-based digital PCR (dPCR) platform under the Clarity product family. The company's core technology is a proprietary high-density chip-in-a-tube partitioning architecture that produces over 40,000 nanoliter partitions per reaction, combined with a 6-color CMOS detection platform that enables multiplexed absolute quantification of DNA and RNA without reference standards. The product ecosystem comprises the Clarity Plus Digital PCR System (Reader, Auto-Loader, Sealing Enhancer, software), the Exponent Thermal Cycler, chip-based consumables (40K and 10K tube-strips) that drive recurring revenue, and a portfolio of pre-formulated and custom assay kits.
JN Medsys monetizes through a hybrid model combining capital equipment sales, single-use consumables, assay kits, and fee-for-service laboratory offerings that include sample analysis, assay development, clinical validation via a Ministry of Health approved clinical laboratory, and NGS services. Go-to-market is executed through direct sales out of Singapore and a network of eight authorized regional distributors across China, Japan, South Korea, India, Taiwan, Vietnam, Indonesia, and Turkey, targeting research and academic institutions as well as clinical and diagnostics companies.
The company's differentiation rests on three pillars: a technically novel partitioning method that competes with Bio-Rad, Thermo Fisher, and Stilla on partition density and dynamic range; an AI-assisted analysis pipeline that automates positive/negative partition classification across tens of thousands of data points per run; and an explicit affordability positioning relative to incumbent dPCR platforms. Visible customers include the National University of Singapore, National Cheng Kung University, the Institute of Molecular and Cell Biology, Nippon Dental University, and DAAN GENE, and the company supports its commercial narrative through a library of peer-reviewed publications.
JN Medsys firmographics
Firmographics- Name
- JN Medsys
- Legal name
- JN Medsys
- Website
- https://jnmedsys.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- JN Medsys is a Singapore-headquartered life science tools company that develops chip-based digital PCR instruments, consumables, assay kits, and laboratory services for absolute nucleic acid quantification, serving academic, clinical diagnostics, and industrial customers across Asia-Pacific via direct sales and eight regional distributors.
- Ownership category
- akta.pro rank
JN Medsys industry classification
Industry- Product category
- Digital PCR Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industries
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
Keywords
Where JN Medsys is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
JN Medsys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Instruments and Hardware: Sale of Clarity Plus Digital PCR system, Clarity Auto-Loader, Clarity Sealing Enhancer, Clarity Plus Reader, and related instrument components.
- Consumables: Sale of proprietary chip-based consumables including 40K and 10K tube-strips, sample loading kits, and sealing fluid. Recurring revenue from consumables as they are single-use per experiment.
- Laboratory Services: Fee-for-service laboratory analysis including digital PCR sample analysis, qPCR services, assay development and validation, clinical validation (Ministry of Health approved clinical laboratory), and next-generation sequencing (NGS) services.
- Assay Kits: Sale of pre-developed and custom assay kits for specific molecular detection applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Clarity Plus Digital PCR System |
Go-to-market motion1 record
Distribution channels9 records
Marketing channels5 records
JN Medsys product offering
Product offeringCore offering
JN Medsys designs, manufactures, and sells high-density chip-based digital PCR (dPCR) systems for absolute quantification of nucleic acids (DNA and RNA). Its flagship Clarity Plus Digital PCR System provides over 40,000 partitions per reaction with 6-colour multiplex detection, complemented by proprietary 40K and 10K chip-in-a-tube consumables, the Exponent Thermal Cycler, assay kits, and fee-for-service laboratory work including sample analysis, assay development, clinical validation, and next-generation sequencing.
Product overview
JN Medsys offers a comprehensive digital PCR ecosystem built around their proprietary high-density chip-based partitioning technology. The core offering consists of the Clarity Plus Digital PCR System (instrument with 6-color detection, up to 96 reactions, 40,000+ partitions per reaction), supported by dedicated Clarity Consumables (40K and 10K tube-strips with chip-in-a-tube design). The system is complemented by the Exponent Thermal Cycler and Assay Kits for complete workflow solutions. All components are designed to work together seamlessly, with automated sample loading via the Auto-Loader and AI-powered software for data analysis.
Differentiator
Problem solved
Functional benefit
Brands
- Clarity: Digital PCR system product line
- Clarity Plus
Products and services
- Clarity Plus Digital PCR System A cutting-edge digital PCR system featuring more than 40,000 partitions per reaction on a high-density chip, delivering high resolution, sensitivity, and dynamic range for RNA and DNA quantification. It includes a 6-colour detection platform for multiplexed quantification of up to 6 targets without reference standards, supports up to 96 reactions per run, and uses AI-powered software for absolute quantification. It is intended for research laboratories, clinical diagnostics developers, and applied testing organizations.
- Clarity Consumables (40K and 10K Tube-Strips) Proprietary single-use chip-in-a-tube consumables for the Clarity / Clarity Plus digital PCR system, available in 40K (40,000-45,000 partitions, 0.3 nL per partition) and 10K (10,000 partitions, 1.3 nL per partition) formats. Each tube-strip holds 8 samples, and the chip design with excess capacity keeps sample loss below 5% while ensuring the entire sample volume is partitioned. Consumables generate recurring revenue for JN Medsys and are intended for any laboratory performing digital PCR experiments.
- Exponent Thermal Cycler A thermal cycler compatible with the Clarity Plus digital PCR system, used to perform PCR amplification of partitioned samples as part of the Clarity workflow. Sold to research and clinical laboratories using the JN Medsys digital PCR platform.
- Assay Kits Pre-formulated and custom assay kits for digital PCR applications, including in-house assays and assays developed against customer specifications for specific research or clinical detection needs. Sold to research and clinical laboratory customers using the Clarity digital PCR platform.
- Sample Analysis Service Fee-for-service laboratory service in which JN Medsys receives customer samples and analyzes and quantifies them using in-house or customer-provided digital PCR and qPCR assays. Targeted at customers who need digital PCR data without running the workflow themselves.
- Assay Development Service Custom assay development service for digital PCR and qPCR, including validation and on-request manufacturing for the customer. Targeted at research and clinical diagnostics customers needing tailored molecular detection assays.
- Clinical Validation Service Clinical laboratory validation of customer diagnostic products for regulatory purposes, performed in JN Medsys' Ministry of Health-approved clinical laboratory. Targeted at diagnostics companies preparing products for regulatory submission.
- Next Generation Sequencing (NGS) Service Next-generation sequencing service run by JN Medsys as an offering for customers who require sequencing in addition to or instead of digital PCR. Targeted at the same research and clinical customers served by the Clarity digital PCR system.
Quantifiable outcome
- Over 40,000 partitions per reaction for single molecule analysis providing higher sensitivity and better accuracy over wider dynamic range
- +2 more outcomes
Companies that use JN Medsys
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
JN Medsys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
JN Medsys partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered standard.
- Hangzhou Neoline Technology Co., Ltd.standardAuthorized distributor for China market covering Hangzhou region with responsibility for sales, support, and distribution of JN Medsys digital PCR products.
- Restar CorporationstandardAuthorized distributor for Japan market providing local sales and distribution of Clarity digital PCR systems and consumables.
- BioD Co., Ltd.standardAuthorized distributor for South Korea market based in Gwangmyeong Technopark.
- Premas Life Sciences Pvt LtdstandardAuthorized distributor for India market based in New Delhi, providing distribution of JN Medsys products.
- EYS Medikal ve Lab. Pro.standardAuthorized distributor for Turkey market providing sales and distribution services.
- Bestgen Biotech Corp.standardAuthorized distributor for Taiwan market based in New Taipei City.
- Suran Medical & Scientific SolutionstandardAuthorized distributor for Vietnam market providing medical and scientific solutions.
- AdvisainsstandardAuthorized distributor for Indonesia market based in Jakarta.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
JN Medsys competitors and assessment
Company assessmentDirect peers
- Bio-Rad Laboratories: Bio-Rad's QX200 and QX600 droplet digital PCR systems are the dominant installed-base competitor to JN Medsys's Clarity Plus, serving similar academic, clinical, and applied-market customers with chip-equivalent partitioning and multiplex workflows.
- QIAGEN: QIAGEN's QIAcuity nanoplates-based dPCR platform competes head-to-head with Clarity Plus in research and clinical labs, offering higher-throughput plates, an IVD-cleared kitted assay menu, and global commercial reach that JN Medsys lacks.
- Stilla Technologies: Stilla's Naica crystal digital PCR system uses similar chip-based partitioning and 6-color multiplex chemistry to Clarity Plus, targeting rare-mutation, liquid-biopsy, and oncology research customers across Europe and North America.
- Standard BioTools: Standard BioTools (formerly Fluidigm) historically sold chip-based dPCR and single-cell genomics instrumentation that competes with JN Medsys's high-density chip partitioning approach, particularly in academic and translational research labs.
Broad incumbents
- Thermo Fisher Scientific: Thermo Fisher's QuantStudio Absolute Q digital PCR system, sold alongside its broader qPCR, NGS, and clinical diagnostics portfolios, overlaps directly with JN Medsys's instrument and consumables offering while leveraging unmatched global service and support infrastructure.
- Roche: Roche's LightCycler and digital PCR roadmap, alongside its diagnostics dominance, makes it a broad incumbent competing with JN Medsys in hospital and clinical-lab nucleic acid quantification workflows.
- Revvity: Revvity (formerly PerkinElmer) sells laboratory automation, qPCR/dPCR reagents, and diagnostic kits that overlap with JN Medsys's consumables, services, and clinical-validation offerings in research and clinical labs.
Regional players
- Da An Gene (DAAN Gene): DAAN Gene is a leading Chinese molecular diagnostics provider that is both a JN Medsys customer and a regional competitor in clinical PCR-based testing, IVD kits, and laboratory services across China and Southeast Asia.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
JN Medsys social profiles
Digital presenceJN Medsys financial estimates
Financial estimateRevenue estimate
Valuation estimate
JN Medsys leadership team
Management profileNumber of profiles
JN Medsys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
JN Medsys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about JN Medsys
What does JN Medsys do?
JN Medsys designs, manufactures, and sells high-density chip-based digital PCR (dPCR) systems for absolute quantification of nucleic acids (DNA and RNA). Its flagship Clarity Plus Digital PCR System provides over 40,000 partitions per reaction with 6-colour multiplex detection, complemented by proprietary 40K and 10K chip-in-a-tube consumables, the Exponent Thermal Cycler, assay kits, and fee-for-service laboratory work including sample analysis, assay development, clinical validation, and next-generation sequencing.
Is JN Medsys a public or private company?
JN Medsys is a private company. It is classified as unknown and is currently operating.
When was JN Medsys founded?
JN Medsys was founded in 2016. It employs 11 to 50 people.
Where is JN Medsys based?
JN Medsys is headquartered in Beijing, China, in the Asia region.
How does JN Medsys make money?
Four revenue lines are on record. Instruments and Hardware is the primary driver. The others are consumables, laboratory Services and assay Kits.
Who are JN Medsys's main competitors?
Direct peers on record are Bio-Rad Laboratories, QIAGEN, Stilla Technologies and Standard BioTools. Broad incumbents are Thermo Fisher Scientific, Roche and Revvity. Da An Gene (DAAN Gene) is listed as a regional player.
Does JN Medsys have an API?
No public API is recorded for JN Medsys.
What industry is JN Medsys in?
JN Medsys's product category is Digital PCR Instrumentation. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.